Cognoa is a pediatric behavioral health company developing digital diagnostics and therapeutics to enable earlier and more equitable diagnosis and treatment of behavioral health conditions, starting with autism. We are dedicated to improving lifelong outcomes for children at risk for developmental delay and their families. Our lead products, the first digital diagnostic device for autism and the first digital therapeutic for children diagnosed with autism, have both received Breakthrough Device designation from the FDA. Cognoa plans to commercialize Canvas Dx™, the first FDA authorized diagnostic device for autism, for U.S. availability beginning in 2023. The company’s AI technology platform will enable Cognoa's product pipeline to address additional conditions including ADHD and childhood anxiety. For additional information and to receive updates on availability for Canvas Dx™, please visit www.Cognoa.com and www.CanvasDx.com.